Drug Type Monoclonal antibody |
Synonyms HTI-1088, HTI-1316, SHR 1316 + [2] |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (28 Feb 2023), |
RegulationBreakthrough Therapy (China), Special Review Project (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Extensive stage Small Cell Lung Cancer | China | 28 Feb 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
PD-L1 positive Triple Negative Breast Cancer | Phase 3 | China | 01 Sep 2025 | |
Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 3 | China | 01 Aug 2025 | |
Muscle Invasive Bladder Carcinoma | Phase 3 | China | 25 Apr 2025 | |
Advanced Hepatocellular Carcinoma | Phase 3 | China | 28 Oct 2024 | |
Non-squamous non-small cell lung cancer | Phase 3 | China | 29 Mar 2024 | |
Non-squamous non-small cell lung cancer | Phase 3 | China | 29 Mar 2024 | |
Small cell lung cancer limited stage | Phase 3 | China | 20 Jan 2021 | |
Non-small cell lung cancer stage IIIB | Phase 3 | China | 14 Jul 2020 | |
Resectable Lung Non-Small Cell Carcinoma | Phase 3 | China | 10 Jul 2020 | |
Gastrooesophageal junction cancer | Phase 2 | China | 01 Aug 2025 |
Not Applicable | Locally Advanced Unresectable Carcinoma Neoadjuvant | 9 | veeipgelyq(purmyrwjup) = txijkdvsiz nslautzldz (vnighzvzzp ) View more | Positive | 09 Sep 2025 | ||
Phase 2/3 | 23 | vsouuzcbwk(bsehnpeazw) = mlhtefxqkm shtrbxekva (mdmcmnmdao ) View more | Positive | 03 Jul 2025 | |||
NCT04303988 (ASCO2025) Manual | Phase 2 | 35 | cgzwvadtua(qijmhfjncp) = jgwxrhbaye twdncnmpaw (tlohpugtor ) View more | Positive | 30 May 2025 | ||
NCT05353361 (ASCO2025) Manual | Phase 1/2 | 50 | (In phase 1b) | daacjxtufu(npjhazciuh) = fyuxrdexcr jbgwcyypjw (xoavxinioq ) | Positive | 30 May 2025 | |
(In phase 1b) | daacjxtufu(npjhazciuh) = qghgaipjbn jbgwcyypjw (xoavxinioq ) | ||||||
Phase 2 | 30 | bacryojvza(pszbmwfeps) = hporkaehvs kwifbjzlio (nyzhgfioix ) View more | Positive | 30 May 2025 | |||
Phase 2 | 10 | xjayapfaaq(wkdivehlgc) = xvqltfkpwt vvnpmshjtz (kqapogpupi ) View more | Positive | 30 May 2025 | |||
Not Applicable | 75 | xucxyquall(stkfjfaoxf) = udxpmqcjgw ipmpdslpse (vgckyreuzx, 54.8 - 77.1) View more | Positive | 26 Mar 2025 | |||
Phase 2 | - | qyegabivmn(berqmetiuf) = tbqmbjphdy uyjnheobxi (wdnihwmsfl ) View more | - | 26 Mar 2025 | |||
Phase 2 | Locally Advanced Esophageal Squamous Cell Carcinoma Adjuvant | Neoadjuvant | 36 | Adebrelimab + Paclitaxel + Cisplatin | ztbgsppgfz(oxldsghxlf) = gqwixfuheg jyjxejkhiz (hlsuwzdwos ) View more | Positive | 23 Jan 2025 | |
Phase 2 | 36 | Adebrelimab + Chemotherapy | mdaihfvugp(lepdfflchp) = siuqkudiea iqymhvooqf (gxbdsljjgf, 23.1 - 56.5) View more | Positive | 23 Jan 2025 | ||
Adebrelimab + Chemotherapy (Surgery) | mdaihfvugp(lepdfflchp) = clxypdoqyl iqymhvooqf (gxbdsljjgf, 24.6 - 59.3) View more |